Last reviewed · How we verify
NCT06860568
The GA in HSI Study
trial testing Retrospective Study in Geographic Atrophy in 42 participants. Completed in 18 February 2025.
18 February 2025
Quick facts
| Lead sponsor | Optina Diagnostics Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 42 |
| Start date | 24 December 2024 |
| Primary completion | 18 February 2025 |
| Estimated completion | 18 February 2025 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Retrospective Study
Conditions studied
- Geographic Atrophy — all drugs for Geographic Atrophy →
- Healthy — all drugs for Healthy →
Sponsor
Optina Diagnostics Inc.
Who can join
50 and older, any sex, with Geographic Atrophy or Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study used a retrospective dataset collected by Optina under different study protocols. The target study population will include adults over the age of 50 years, with and without the presence of AMD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06860568
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Retrospective Study
Trials testing the same drug.
- NCT03563976 — Multiparametric Image Analysis and Correlation With Outcomes in Lung Cancer Screening and Early Stage Lung Cancer · recruiting
Other recruiting trials for Geographic Atrophy
Currently open trials in the same condition.
- NCT07215234 — A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Se · Phase 1, PHASE2 · recruiting
- NCT06961370 — A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO76693 · Phase 1 · recruiting
- NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
- NCT06769048 — A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) C · Phase 2 · active not recruiting
- NCT06805474 — A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT · recruiting
Other Optina Diagnostics Inc. trials
Trials by the same sponsor.
- NCT05903664 — Retinal Deep Phenotyping.TM · withdrawn
- NCT06057493 — RDP Reliability Study · completed
- NCT05903651 — Retinal Deep PhenotypingTM · completed
- NCT06860555 — Hyperspectral Drusen Classification · completed
- NCT05199428 — Optina Eye to Heart Connection · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06860568 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Optina Diagnostics Inc.
- Last refreshed: 6 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06860568.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing